Chartis Acquires Leap AI, Pivoting from Advisor to AI Solution Builder

CHICAGO, IL – March 19, 2026 – In a strategic move that signals a significant shift in the healthcare consulting landscape, advisory firm Chartis today announced its acquisition of Leap AI, a startup specializing in generative AI solutions for the healthcare sector. The deal moves Chartis beyond its traditional role as a strategic advisor and squarely into the realm of technology development, aiming to build and deploy custom AI tools designed to tackle the industry's most persistent challenges.

Leap AI, a venture studio founded in 2023, will be integrated into the Chartis Center for AI & Digital Transformation. The new entity, branded as Chartis Leap AI Studio, will be led by Leap AI's senior leadership, who bring deep technical expertise in creating AI-enabled products for everything from workflow automation to complex research and development.

This acquisition arrives as healthcare organizations grapple with the promise and peril of artificial intelligence. While major consulting firms like Deloitte and Accenture are actively advising clients on AI strategy, Chartis's decision to buy a development-focused company represents a more direct, hands-on approach, betting that the future of healthcare transformation lies not in generic platforms but in highly tailored technological interventions.

Beyond Off-the-Shelf: A Bet on Bespoke AI

The core logic behind the acquisition is a rejection of one-size-fits-all solutions. Chartis leadership argues that the unique complexities of healthcare providers—with their disparate data systems, legacy infrastructure, and distinct operational workflows—demand a more customized approach.

"As AI becomes industrialized across healthcare, organizations risk losing the ability to innovate against their unique friction points. Off-the-shelf platforms can't match solutions built around an organization's specific challenges, data, and operations," said Chartis Chief AI & Digital Officer Tom Kiesau. He emphasized that the goal is to combine Leap AI's technical prowess with Chartis's deep industry knowledge to co-create solutions with clients.

This strategy directly confronts a major pain point for healthcare executives. Many have found that generic AI platforms require extensive, costly customization to become effective, often failing to deliver on their initial promise. The new Chartis Leap AI Studio aims to bypass this issue by starting with a client's specific problem—be it patient scheduling, clinical trial recruitment, or supply chain management—and building a solution from the ground up. This model promises a higher degree of integration and, theoretically, a greater return on investment by avoiding the dreaded "pilot purgatory," where promising technologies fail to scale across an enterprise.

From Advisor to Innovator: Reshaping the Consultancy Model

For decades, Chartis has built its reputation on providing strategic, operational, and clinical advice to over 1,900 organizations annually. This acquisition marks a fundamental evolution of its business model, moving from simply advising on transformation to actively building the tools that drive it. It's a transition from strategy to execution, reflecting a broader trend where professional services firms are embedding technology development capabilities directly into their offerings.

Leap AI’s team will form the core of the new studio, tasked with maintaining a pipeline of future-focused ideas. Their venture studio background, which involved incubating and de-risking innovative healthcare AI concepts, provides Chartis with an engine for rapid prototyping and safe, contained testing of new use cases.

"We're excited to join Chartis and expand the impact of our new colleagues," said Ali Paasimaa, who will now serve as Senior Partner and Head of Chartis Leap AI. "Chartis is widely recognized as a leader in healthcare transformation, with deep strategic, clinical, and operational expertise. By combining that foundation with Leap AI's entrepreneurial energy and technical depth, we'll deliver AI solutions that meaningfully improve how healthcare organizations operate and how patients experience care."

This integrated model—combining deep domain consulting with agile product development—positions Chartis to offer an end-to-end service that few competitors can match. The firm is betting that clients will prefer a single partner that can diagnose a problem, design a strategy, build the technology, and help implement the operational changes necessary for success.

Harnessing Generative AI for Healthcare's Core Challenges

The technological centerpiece of this deal is Leap AI's expertise in generative AI. Before the acquisition, the startup was working in stealth on several high-impact areas, including optimizing patient recruitment for clinical trials, managing genomic data, and improving care for individuals with chronic diseases. This focus on using generative AI to solve specific, high-value problems is what made it an attractive target.

For Chartis's clients, the applications could be transformative. Generative AI can be used to automate the crushing burden of clinical documentation, a primary driver of physician burnout, by converting doctor-patient conversations into structured notes. In research, it can accelerate drug discovery by analyzing vast datasets to identify new therapeutic targets. For patients, it can power personalized care plans and create more intuitive, responsive user experiences for navigating complex healthcare systems.

By establishing the Chartis Leap AI Studio, the firm can now offer clients a dedicated environment to explore these possibilities. The studio will function as a sandbox for innovation, allowing health systems to test how generative AI can be safely and effectively applied to their unique environments before committing to a full-scale deployment.

Navigating a Complex Ethical and Regulatory Maze

While the potential of this new venture is immense, so are the challenges. Deploying generative AI in a clinical setting is fraught with ethical, regulatory, and privacy-related complexities. The risk of algorithmic bias, where AI models perpetuate existing health inequities, is a primary concern. Furthermore, the "black box" nature of some AI models can create issues with trust and accountability, while the potential for AI to generate inaccurate information, or "hallucinate," poses a serious patient safety risk.

Navigating this landscape will require more than just technical skill. It demands a sophisticated understanding of regulatory frameworks like HIPAA in the U.S. and the EU's stringent AI Act. It also requires a commitment to ethical principles, including transparency, fairness, and robust human oversight. Chartis is positioning its long history and deep expertise in healthcare as a key asset in managing these risks.

The success of the Chartis Leap AI Studio will ultimately depend on its ability to balance rapid innovation with rigorous governance. By creating solutions that are not only technologically advanced but also safe, equitable, and trustworthy, Chartis aims to set a new standard for how AI is developed and deployed to finally make U.S. healthcare more affordable, accessible, and human.